Follicle stimulating hormone glyco-optimised - Glycotope

Drug Profile

Follicle stimulating hormone glyco-optimised - Glycotope

Alternative Names: Follicle stimulating hormone - Glycotope; FSH-GEX; Glyco-optimized follicle-stimulating hormone - Glycotope; GT-GP-2.4 GEX

Latest Information Update: 13 Jul 2016

Price : $50

At a glance

  • Originator Glycotope
  • Class Follicle stimulating hormones; Infertility therapies; Pituitary gonadotropins
  • Mechanism of Action Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Female infertility

Most Recent Events

  • 13 Jul 2016 Phase-III clinical trials in Female infertility (SC) before July 2016
  • 04 Sep 2015 Clinical development of follicle stimulating hormone glyco-optimized is ongoing
  • 26 Mar 2014 Glycotope completes a phase II trial in Female infertility in Germany (EudraCT 2012-003006-27)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top